Chimerix, Inc. (CMRX)
| Market Cap | 270.71M |
| Revenue (ttm) | 159,000 |
| Net Income (ttm) | -83.59M |
| Shares Out | 89.94M |
| EPS (ttm) | -0.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 326,604 |
| Open | 3.150 |
| Previous Close | 2.990 |
| Day's Range | 2.910 - 3.170 |
| 52-Week Range | 0.750 - 3.390 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+182.39%) |
| Earnings Date | Nov 7, 2024 |
About CMRX
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary c... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CMRX stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 182.39% from the latest price.
News
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diff...
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, ...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards ...
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET Company Participants Will O'Connor - Investor Relations Mike Andriole - President and Chief Executive Officer Josh Allen...
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement awar...
Chimerix, Inc. (CMRX) Q2 2024 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Mike Andriole - President and Chief Executive Of...
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients ...
Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Will O'Connor – Stern Investor Relations Mike Andriole – President and Chief Executive Office...
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 –
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fa...
Chimerix: Tackling A Strong Unmet Need With Promising Data
Chimerix, Inc. is a biotech company focused on developing novel treatments for high-grade glioma and other therapies. Their main clinical asset, doraviprone, has shown promising results in treating H3...
Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript
Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix Appoints Lisa Decker to Board of Directors
Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Exp...
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
DURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development Seasoned Executive Brings More Than 25 Years of Industry...
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 –
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix: Dangerous Road, Thesis Intact
Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite expe...
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control
Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of Strategic Planning and Investor Relations Mike Andr...
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 –
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...